Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika

Project description

Developing the first antivirals against dengue

Flavivirus outbreaks annually impact 40 % of the world’s population, leading to over 395 million infections, 25 000 deaths (primarily among children), 750 000 disability-adjusted life years, and direct and indirect costs exceeding EUR 9 billion. Currently, there are no effective treatments or vaccines available. Protinhi Therapeutics is working on developing broad-spectrum antivirals targeting flaviviruses such as dengue, Zika and West Nile. The EIC-funded ATLAS project aims to achieve a significant breakthrough in the development of broad-spectrum antivirals, representing a pioneering effort to address the global health emergency resulting from flaviviral infections. Protinhi will conduct clinical trial-enabling studies and pharmaceutical development to establish proof of concept in humans, progressing through Phase I and Phase IIa clinical trials focused on the most common flavivirus, dengue.

Objective

WHO, governments and health institutes are urgently seeking methods to prevent future catastrophic flavivirus outbreaks affecting millions (annually >40% of the global population at risk, resulting in ~395M infections, >25,000 deaths of which mainly children, 750.000 disability-adjusted life years and >9B direct & indirect costs). As there are no effective treatments or vaccines available, ATLAS will provide a breakthrough in broad-spectrum antivirals: the first-in-class drug to combat the global health emergency of flaviviral infections. In the ATLAS project, Protinhi will finalize clinical trial-enabling studies and pharmaceutical development and obtain proof-of-concept in humans by conducting Phase I and Phase IIa clinical trials against the most common flavivirus: dengue. This will put the company in an excellent position to attract interest from pharmaceutical companies (e.g. Gilead, J&J, MSD) for a strategic partnership for late clinical development and commercialization.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

PROTINHI BV
Net EU contribution
€ 2 499 999,00
Address
TRANSISTORWEG 5
6534 AT Nijmegen
Netherlands
SME
Yes
Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 14 465 988,75